{"id":"W2466927139","doi":"10.1080/13543776.2016.1206080","title":"Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Fondation Leducq","keywords":"PCSK9; Alirocumab; Evolocumab; Kexin; Proprotein convertase; Dyslipidemia; Medicine; Pharmacology; Monoclonal antibody; Cholesterol; LDL receptor; Antibody; Internal medicine; Immunology; Lipoprotein; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002793901,0.001043537,0.004231293,0.0002239696,0.0001840932,0.00003248457,0.000493785,0.0007015133,0.0005148406],"category_scores_gemma":[0.00003535756,0.0004685302,0.001392045,0.0002733706,0.0003894324,0.0001295995,0.000105397,0.0007916604,0.0001182161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002027106,"about_ca_system_score_gemma":0.0005779772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001421914,"about_ca_topic_score_gemma":0.00000179406,"domain_scores_codex":[0.9928669,0.002415459,0.001728631,0.001081745,0.001263208,0.0006440197],"domain_scores_gemma":[0.9957718,0.000102885,0.001093691,0.002301323,0.0002959144,0.0004343719],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005709112,0.0002853962,0.000008512243,0.008240288,0.001086024,0.000009889593,0.0001385319,8.606741e-9,0.000009612322,0.0001475664,0.00279816,0.9867051],"study_design_scores_gemma":[0.005230188,0.0007805369,0.00003338528,0.05146978,0.0002456456,0.00008790877,0.00004413003,0.000002822119,0.00007980965,0.00004589388,0.9414789,0.0005010023],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003268545,0.9858541,0.00002030571,0.002745249,0.001743748,0.009362099,0.0001021481,0.00009113614,0.00004845729],"genre_scores_gemma":[0.0001224274,0.9921029,0.00003511239,0.003765591,0.001823446,0.001151257,0.0006651643,0.0001828215,0.0001513227],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9862041,"threshold_uncertainty_score":0.9997767,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08188793832644997,"score_gpt":0.3603073481168442,"score_spread":0.2784194097903943,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}